Sobi to Present New Aspaveli/Empaveli Data at ASN Kidney Week 2026
Sobi announced seven abstracts on Aspaveli/Empaveli (pegcetacoplan) have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2026. The event takes place in Denver, Colorado, from October 21–25.
Sobi will present seven abstracts detailing the use and efficacy of its drug pegcetacoplan, marketed as Aspaveli and Empaveli, at the American Society of Nephrology (ASN) Kidney Week 2026. The conference is scheduled to take place in Denver, Colorado, from October 21 to 25.
The presented data will focus on Aspaveli/Empaveli's role in the treatment of kidney diseases. According to the company, the presentations will cover a range of findings, including clinical development and treatment outcomes.
ASN Kidney Week is a significant annual gathering for nephrology professionals, serving as a platform to share the latest advancements in kidney disease research, diagnosis, and treatment.
Pegcetacoplan is a complement inhibitor being developed for various rare kidney diseases. Sobi anticipates that the data presented at the conference will offer further insights into the drug's therapeutic potential for patients.